Anti-CD14 Treatment With IC14 in Hospitalized ARDS Patients (NCT06513949)
Phase 2, Randomized, Double-Blind, Placebo-Controlled, Safety and Efficacy Study of Anti-CD14 Treatment With a Recombinant Chimeric Monoclonal Antibody (IC14) in Hospitalized Patients With Acute Respiratory Distress Syndrome
🩺 Plain-English Summary (8th-Grade Level)
Hospitalized patients with ARDS will be randomized to intravenous treatment with a monoclonal antibody against CD14, called IC14, or placebo. They will be followed for 28 days. The primary outcome is the day 4 oxygenation index assessed as a continuous measure.
Who can join: Review the eligibility criteria below.
Location: Harborview Medical Center — Seattle, Washington
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- Harborview Medical Center — Seattle, Washington
- University of Washington — Seattle, Washington
📞 Contact the Study Coordinator
Phone: (206) 897-5051
Email: mflinzee@uw.edu
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Respiratory Distress Syndrome
- Identification and Treatment of Hypoxemic Respiratory Failure and ARDS With Protection, Paralysis, and Proning Pathway — Calgary, Alberta
- Molecular Epidemiology of Acute Respiratory Distress Syndrome (ARDS) — Boston, Massachusetts
- ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND) — Birmingham, Alabama
- Precision Ventilation vs Standard Care for Acute Respiratory Distress Syndrome — Tucson, Arizona
- Macrophage Programing in Acute Lung Injury: MiniBAL — Denver, Colorado
- Vascular ARDS Recruitment After Inhaled Nitric Oxide — Boston, Massachusetts
Explore by condition: All Acute Respiratory Distress Syndrome clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.